Determination of ursodeoxycholic acid in serum by a new fluorometric enzymatic method using 7β-hydroxysteroid dehydrogenase from Clostridium absonum

Lianidou, Evi; Papastathopoulos, D.S.; Siskos, P. A.

doi:10.1016/0003-2697(89)90140-1

Cited by 7 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity, specificity, accuracy, reproducibility, and linearity of this enzyme assay is documented 3 . This enzyme has been supplied to others to measure UDCA in serum 4 …”

Section: Methodsmentioning

confidence: 99%

Bioavailability of four ursodeoxycholic acid preparations

Williams

Al-Knawy

Blanchard

2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Ursodeoxycholic acid (UDCA) is the drug of choice for treating primary biliary cirrhosis and dissolving cholesterol gallstones. Objectives: The objective of this study was to compare the bioavailability of four commercially available ursodeoxycholic acid formulations in standardized doses. Methods: Twenty‐four healthy subjects were studied in groups of four, and received each of the different UDCA preparations in random order, with a 1‐week washout or more in‐between. Serum UDCA levels were determined for a 6‐h period. The mean area under the curve (AUC), Cmax and Tmax were determined for each drug formulation, and the results compared. Dose proportionality was determined using the Canadian Ursofalk tablet using either 250 mg, 500 mg or 750 mg dosing. The intraparticipant variability was assessed by asking each participant to repeat the last drug that they took the second time, 1 week later. Results: The mean AUC was 68.99 μmol/1.6 h−1 for the USA UDCA tablet, 59.34 μmol/1.6 h−1 for the Canadian UDCA tablet, 55.55 μmol/1.6 h−1 for Ursolvan capsules, and 46.66 μmol/1.6 h−1 for Actigall capsules. The mean Cmax values were 24.29, 17.85, 16.63 and 413.32 nmol/mL, respectively. The mean Tmax was 1.82, 2.3, 2.79 and 3.39 h, respectively. Linear aggression analysis assessing the direct proportionality of AUC on the dose for the Canadian UDCA tablet gave an estimate of 0.063 + 0.0164 (standard error, P‐value=0.0117), e.g. if the dose increases from 250 mg to 500 mg, the serum ursodeoxycholic acid increases by 250 × 0.063=15.75. There was excellent reproducibility for the AUC for the North American tablets (0.97, 0.88) compared to the two capsules (0.32, 0.15). Conclusions: The significantly higher AUC and Cmax and shorter Tmax for the Canadian Ursofalk tablets compared to the UDCA capsule preparations supports better bioavailability.

show abstract

“…The sensitivity, specificity, accuracy, reproducibility, and linearity of this enzyme assay is documented 3 . This enzyme has been supplied to others to measure UDCA in serum 4 …”

Section: Methodsmentioning

confidence: 99%

Bioavailability of four ursodeoxycholic acid preparations

Williams

Al-Knawy

Blanchard

2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Among the methods described in the literature, there are HPLC methods with ultraviolet, fluorescence or refractive index detection [4][5][6][7][8][9][10], HPLC with mass spectrometric detection [11,12] or gas chromatography with mass spectrometric detection [1,[12][13][14][15]. With most of these methods, free and conjugated bile acids are not analyzed simultaneously.…”

Section: Introductionmentioning

confidence: 99%

High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma

Tessier

Neirinck

Zhu

2003

Journal of Chromatography B

View full text Add to dashboard Cite

“…Ursodiol, 3α,7β-dihydroxy-5β-cholan-24-oic acid is a naturally occurring bile acid found in small quantities in human plasma. Ursodeoxycholic acid regulates cholesterol by reducing the rate at which the intestine absorbs cholesterol molecules [1][2][3] . In the liver it is conjugated with glycine or taurine and then secreted into the hepatic bile ducts.…”

Section: Introductionmentioning

confidence: 99%

Liquid Chromatography/Tandem Mass Spectrometry for the Simultaneous Determination of Ursodiol and its Major Metabolites, Tauroursodeoxycholic Acid and Glycoursodeoxycholic Acid in Human Plasma

Ganesan

Nanjundan

Sekarbabu

et al. 2012

Journal of Chemistry

View full text Add to dashboard Cite

A rapid and sensitive method is described for the quantification of ursodiol and its major metabolites glycoursodeoxycholic acid (GUDCA) and tauroursodeoxycholic acid (TUDCA) in human plasma using single internal standard (Ursodeoxycholic Acid d4). Solid phase extraction was performed and chromatographic separation of 5µL injected sample was achieved using Waters Xterra, 5µm column with a mobile phase comprised of methanol and 5 mM ammonium formate with 0.1 % acetic acid ( 70 : 30, v/v ). The mass spectrometer was used in negative ion mode and multiple reactions monitoring using electro spray ionization mode as an interface. The method was fully validated and the calibration curves were linear over the concentration range of 25.9 to 15300.1 ng/mL for ursodiol, 2.7 to 1587.5ng/mLfor tauroursodeoxycholicacid and 25.4 to 15040.9 ng/mL for glycoursodeoxycholic acid. The method was sensitive and specific, with the lower limit of quantification of 25.9, 2.7 and 25.4 ng/ml for ursodiol, tauroursodeoxycholic acid and glycoursodeoxycholic acid respectively. The present method includes a simple and rapid sample preparation with shorter analysis run time and less flow rate compared to previously reported methods. The method was applied successfully for a bioequivalence study in healthy subjects.

show abstract

Determination of ursodeoxycholic acid in serum by a new fluorometric enzymatic method using 7β-hydroxysteroid dehydrogenase from Clostridium absonum

Cited by 7 publications

References 25 publications

Bioavailability of four ursodeoxycholic acid preparations

Bioavailability of four ursodeoxycholic acid preparations

High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma

Liquid Chromatography/Tandem Mass Spectrometry for the Simultaneous Determination of Ursodiol and its Major Metabolites, Tauroursodeoxycholic Acid and Glycoursodeoxycholic Acid in Human Plasma

Contact Info

Product

Resources

About